Palakuri Surender, Chandra Alok, Prakash Sudeep, Manrai Manish, Muthukrishnan J, Srivastava Sharad, Dawra Saurabh
Resident, Department of Medicine, Armed Forces Medical College, Pune, India.
Consultant (Medicine), Command Hospital (Southern Command), Pune, India.
Med J Armed Forces India. 2025 Jan-Feb;81(1):58-65. doi: 10.1016/j.mjafi.2024.02.003. Epub 2024 Apr 8.
Acute-on-chronic liver failure (ACLF) is a life threatening disease. This study seeks to identify factors that contribute to greater financial burden in ACLF.
In total, 55 patients were included. ACLF was defined as per 'European Association for the Study of the Liver-Chronic liver failure (EASL-CLIF)' criteria. Patient's sociodemographic profile, comorbidities, clinical features as well as 'Child-Turcotte-Pugh (CTP)' score, 'Model for end stage liver disease-Sodium (MELD-Na)', 'Acute physiology and chronic health evaluation (APACHE-II)' and sequential organ failure assessment score (SOFA) scores were recorded. Direct costs (medicines, doctor visits, investigations, procedures, treatment), direct non-medical cost (transportation, food and accommodation), and indirect costs (due to loss of productivity by patient and care giver) were calculated. All charges were as prescribed by central government health scheme (CGHS). Patients were followed till discharge/death.
The mean cost of management of ACLF was Indian Rupee (₹) 178,483 ± 83,460, equivalent to United States Dollars ($) 2174.69 ± 1016.90. The direct medical costs, direct non-medical costs and indirect costs were ₹134,310 ± 62,796 (1639.56 ± 766.5$), 13,809 ± 8455 (168.5 ± 103.2$) and ₹0.30,364 ± 21,142 (370.6 ± 258 $), respectively.There was no significant correlation between total cost and demographic and clinical variables. Length of intensive care unit (ICU) stay incurred higher cost (p < 0.0001). We found direct positive correlation between total cost of management and ICU stay (R = 0.80) and duration of hospital stay (R = 0.77). A negative correlation was revealed between total cost of managing ACLF and APACHE-II score (R = -0.10), MELD-Na score (R = -0.13).
The current study can serve as a benchmark for future research on ACLF cost management.
慢加急性肝衰竭(ACLF)是一种危及生命的疾病。本研究旨在确定导致ACLF患者经济负担加重的因素。
共纳入55例患者。ACLF根据“欧洲肝脏研究协会-慢性肝衰竭(EASL-CLIF)”标准进行定义。记录患者的社会人口统计学特征、合并症、临床特征以及“Child-Turcotte-Pugh(CTP)”评分、“终末期肝病-钠(MELD-Na)”模型、“急性生理与慢性健康状况评估(APACHE-II)”和序贯器官衰竭评估评分(SOFA)。计算直接成本(药品、医生诊疗、检查、手术、治疗)、直接非医疗成本(交通、食品和住宿)以及间接成本(患者和照顾者生产力损失所致)。所有费用均按照中央政府健康计划(CGHS)规定收取。对患者进行随访直至出院/死亡。
ACLF的平均管理成本为178483印度卢比(₹)±83460,相当于2174.69美元($)±1016.90。直接医疗成本、直接非医疗成本和间接成本分别为134310印度卢比(₹)±62796(1639.56美元($)±766.5)、13809印度卢比(₹)±8455(168.5美元($)±103.2)和30364印度卢比(₹)±21142(370.6美元($)±258)。总成本与人口统计学和临床变量之间无显著相关性。重症监护病房(ICU)住院时间导致更高的成本(p < 0.0001)。我们发现管理总成本与ICU住院时间(R = 0.80)和住院时间(R = 0.77)之间存在直接正相关。ACLF管理总成本与APACHE-II评分(R = -0.10)、MELD-Na评分(R = -0.13)之间呈负相关。
本研究可为未来ACLF成本管理研究提供基准。